Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche reports positive haemophilia A study data for emicizumab

Roche reports positive haemophilia A study data for emicizumab

18th July 2017

Roche has announced the publication of new clinical trial data that demonstrates the safety and efficacy of emicizumab in the treatment of haemophilia A.

Results from the HAVEN 1 phase III study, which evaluated once-weekly subcutaneous emicizumab prophylaxis in adults and adolescents with haemophilia A with inhibitors, have been published in the New England Journal of Medicine.

A clinically meaningful and statistically significant reduction of 87 percent was observed in the number of treated bleeds with prophylactic emicizumab when compared with on-demand treatment, while all 12 secondary endpoints also delivered positive results.

These included a statistically significant reduction of 79 percent in treated bleeds in a first-of-its-kind intra-patient analysis of a subset of patients comparing two prophylaxis regimens.

Data from this study and HAVEN 2, which assessed the drug's performance in children younger than 12 years of age, will support future regulatory applications for emicizumab.

Dr Sandra Horning, Roche's chief medical officer and head of global product development, said: "We believe emicizumab has the potential to make a meaningful difference for people with haemophilia A with inhibitors, while also reducing the burden of managing the condition with a subcutaneous once-weekly administration."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801837916-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.